Antigenic peptide binding by class I and class II histocompatibility proteins - PubMed (original) (raw)

Review

Antigenic peptide binding by class I and class II histocompatibility proteins

L J Stern et al. Structure. 1994.

Abstract

The recent determination of the structure of a class II MHC molecule complexed to a specific peptide reveals both similarities and differences with peptide binding by class I MHC.

PubMed Disclaimer

Similar articles

• Antigen presentation. One size fits all.
  Rothbard JB. Rothbard JB. Curr Biol. 1994 Jul 1;4(7):653-5. doi: 10.1016/s0960-9822(00)00146-9. Curr Biol. 1994. PMID: 7953548 Review.
• Peptide binding by class I and class II MHC molecules.
  Batalia MA, Collins EJ. Batalia MA, et al. Biopolymers. 1997;43(4):281-302. doi: 10.1002/(SICI)1097-0282(1997)43:4<281::AID-BIP3>3.0.CO;2-R. Biopolymers. 1997. PMID: 9316393 Review.
• Structures of an MHC class II molecule with covalently bound single peptides.
  Fremont DH, Hendrickson WA, Marrack P, Kappler J. Fremont DH, et al. Science. 1996 May 17;272(5264):1001-4. doi: 10.1126/science.272.5264.1001. Science. 1996. PMID: 8638119
• Analysis of the structure of naturally processed peptides bound by class I and class II major histocompatibility complex molecules.
  Appella E, Padlan EA, Hunt DF. Appella E, et al. EXS. 1995;73:105-19. doi: 10.1007/978-3-0348-9061-8_6. EXS. 1995. PMID: 7579970 Review.
• Highly conserved, potential cleavage sites about the desetopes of MHC class I and class II molecules.
  Lam V, Thomas LJ, Kostyal DA, Humphreys RE. Lam V, et al. Tissue Antigens. 1992 Jan;39(1):26-31. doi: 10.1111/j.1399-0039.1992.tb02152.x. Tissue Antigens. 1992. PMID: 1542874 No abstract available.

Cited by

• Immunoinformatics Design and In Vivo Immunogenicity Evaluation of a Conserved CTL Multi-Epitope Vaccine Targeting HPV16 E5, E6, and E7 Proteins.
  Guo N, Niu Z, Yan Z, Liu W, Shi L, Li C, Yao Y, Shi L. Guo N, et al. Vaccines (Basel). 2024 Apr 9;12(4):392. doi: 10.3390/vaccines12040392. Vaccines (Basel). 2024. PMID: 38675774 Free PMC article.
• Unconventional modes of peptide-HLA-I presentation change the rules of TCR engagement.
  Hopkins JR, MacLachlan BJ, Harper S, Sewell AK, Cole DK. Hopkins JR, et al. Discov Immunol. 2022 May 4;1(1):kyac001. doi: 10.1093/discim/kyac001. eCollection 2022. Discov Immunol. 2022. PMID: 38566908 Free PMC article. Review.
• Structure-aware deep model for MHC-II peptide binding affinity prediction.
  Yu Y, Zu L, Jiang J, Wu Y, Wang Y, Xu M, Liu Q. Yu Y, et al. BMC Genomics. 2024 Jan 30;25(1):127. doi: 10.1186/s12864-023-09900-6. BMC Genomics. 2024. PMID: 38291350 Free PMC article.
• HLA class I peptide polymorphisms contribute to class II DQβ0603:DQα0103 antibody specificity.
  Shih NR, Nong T, Murphey C, Lopez-Cepero M, Nickerson PW, Taupin JL, Devriese M, Nilsson J, Matignon MB, Bray RA, Lee JH. Shih NR, et al. Nat Commun. 2024 Jan 19;15(1):609. doi: 10.1038/s41467-024-44912-0. Nat Commun. 2024. PMID: 38242876 Free PMC article.
• Unveiling the Immunogenicity of Ovarian Tumors as the Crucial Catalyst for Therapeutic Success.
  Rodriguez GM, Yakubovich E, Vanderhyden BC. Rodriguez GM, et al. Cancers (Basel). 2023 Dec 2;15(23):5694. doi: 10.3390/cancers15235694. Cancers (Basel). 2023. PMID: 38067396 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations

• Research Materials

  • NCI CPTC Antibody Characterization Program